uniQure (NASDAQ:QURE) Trading Down 4.3% - Should You Sell?

Key Points

• uniQure's stock fell 4.3% during mid-day trading, reaching a price of $16.73, significantly reducing its trading volume by 60% compared to the average.
• Analysts have mixed ratings on uniQure, with a general average rating of "Buy" and a price target of $37.45, while recent reports suggest a target price ranging from $30.00 to $70.00.
• The company reported a quarterly earnings loss of ($0.69) EPS, which was better than expected, revealing revenue of $5.26 million against estimates of $5.00 million.

uniQure N.V. (NASDAQ:QURE - Get Free Report)'s share price fell 4.3% during mid-day trading on Thursday . The stock traded as low as $17.04 and last traded at $16.73. 534,745 shares were traded during trading, a decline of 60% from the average session volume of 1,344,438 shares. The stock had previously closed at $17.48.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on QURE. HC Wainwright restated a "buy" rating and set a $70.00 target price on shares of uniQure in a research report on Friday, September 5th. Cantor Fitzgerald set a $47.00 price objective on uniQure in a research report on Wednesday, July 30th. Chardan Capital reiterated a "buy" rating and issued a $35.00 price objective on shares of uniQure in a research report on Monday. Wall Street Zen upgraded uniQure from a "sell" rating to a "hold" rating in a research report on Saturday, August 2nd. Finally, Mizuho upgraded uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 price objective for the company in a research report on Thursday, August 14th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $37.45.

uniQure Trading Down 3.1%

The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98. The business has a 50-day simple moving average of $15.19 and a two-hundred day simple moving average of $13.90. The stock has a market cap of $929.50 million, a price-to-earnings ratio of -4.32 and a beta of 0.14.

uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.The company had revenue of $5.26 million for the quarter, compared to analysts' expectations of $5.00 million. As a group, research analysts forecast that uniQure N.V. will post -3.75 EPS for the current year.

Insider Activity at uniQure

In other news, Director Jack Kaye sold 2,112 shares of the company's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $30,518.40. Following the sale, the director owned 20,439 shares in the company, valued at $295,343.55. This represents a 9.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Rachelle Suzanne Jacques sold 2,112 shares of the company's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $30,518.40. Following the sale, the director owned 28,346 shares in the company, valued at approximately $409,599.70. This represents a 6.93% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,144 shares of company stock worth $322,426. Insiders own 4.79% of the company's stock.

Institutional Investors Weigh In On uniQure

A number of large investors have recently added to or reduced their stakes in QURE. Jefferies Financial Group Inc. bought a new stake in uniQure in the 2nd quarter valued at $29,217,000. Vestal Point Capital LP raised its stake in uniQure by 58.4% in the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock valued at $50,801,000 after acquiring an additional 1,767,572 shares during the period. JPMorgan Chase & Co. raised its stake in uniQure by 471.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company's stock valued at $25,199,000 after acquiring an additional 1,491,486 shares during the period. Sofinnova Investments Inc. raised its stake in uniQure by 185.5% in the 2nd quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company's stock valued at $21,723,000 after acquiring an additional 1,012,585 shares during the period. Finally, RTW Investments LP raised its stake in uniQure by 8,936.3% in the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company's stock valued at $15,958,000 after acquiring an additional 893,625 shares during the period. Institutional investors own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.